New hope for rare tumor patients: AL102 drug trial launches
NCT ID NCT04871282
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a drug called AL102 (varegacestat) in people with desmoid tumors that are growing. Desmoid tumors are non-cancerous but can be painful and invasive. The trial has two parts: Part A checks safety and tumor changes, and Part B compares AL102 to a placebo to see if it delays tumor growth. About 198 adults with progressing desmoid tumors are taking part.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- AL102 (varegacestat), a gamma-secretase inhibitor
- What this could lead to
- If successful, AL102 could offer a new treatment option to slow or stop the growth of desmoid tumors, potentially reducing the need for surgery or other therapies.
- What could go wrong
- This is a mid-stage trial with only 198 participants, so results may not apply to all patients. The drug may cause side effects or fail to show meaningful benefit over placebo.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DESMOID are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
ASAN Medical Center
Seoul, 43-gil, South Korea
-
Addenbrooke's Hospital
Cambridge, CB2 0QQ, United Kingdom
-
Adelaide Cancer Centre
Kurralta Park, South Australia, 5037, Australia
-
Campus Bio-Medico University Hospital
Rome, 00128, Italy
-
Catalan Institute of Oncology (ICO)
Barcelona, 08908, Spain
-
Chris O'Brien Lifehouse
Camperdown, New South Wales, 2050, Australia
-
City of Hope
Duarte, California, 91010, United States
-
Cleveland Clinic
Cleveland, Ohio, 44195, United States
-
Columbia University Irving Medical Center
New York, New York, 10032, United States
-
Erasmus Medisch Centrum
Rotterdam, 3015 AA, Netherlands
-
Fox Chase Cancer Center
Philadelphia, Pennsylvania, 19111, United States
-
Fred Hutchinson Cancer Center
Seattle, Washington, 98109, United States
-
Hadassah University Hospital - Ein Kerem
Jerusalem, 9112001, Israel
-
Helios Klinikum Berlin-Buch
Berlin, 13125, Germany
-
Hospital Universitario 12 de Octubre
Madrid, 28041, Spain
-
Hospital Universitario Fundacion Jimenez Diaz
Madrid, 28040, Spain
-
Hospital Universitario Miguel Servet
Zaragoza, 50009, Spain
-
IRCCS Fondazione Istituto Nazionale dei Tumori
Milan, 20133, Italy
-
IRCCS Istituto Ortopedico Rizzoli
Bologna, 40136, Italy
-
Jefferson City Medical Group
Jefferson City, Missouri, 65109, United States
-
Jefferson University Hospital
Philadelphia, Pennsylvania, 19107, United States
-
Leiden University Medical Center
Leiden, Netherlands
-
Levine Cancer Institute
Charlotte, North Carolina, 28204, United States
-
MD Anderson Cancer Center
Houston, Texas, 77005, United States
-
Mannheim university medical center
Mannheim, 68167, Germany
-
Maria Sklodowska-Curie National Research Institute of Oncology
Warsaw, 00-001, Poland
-
Massachusetts General Hospital
Boston, Massachusetts, 02214, United States
-
Mayo Clinic
Pheonix, Arizona, 85054, United States
-
Mayo Clinic
Jacksonville, Florida, 32224, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
NorthShore University Health System
Evanston, Illinois, 60201, United States
-
Ohio State University Wexner Medical Center
Columbus, Ohio, 43210, United States
-
Oncology Institute Barzilai Medical Center
Ashkelon, Israel
-
Oregon Health & Science University
Portland, Oregon, 97239, United States
-
Peter MacCallum Cancer Centre
Melbourne, Victoria, 3000, Australia
-
Princess Alexandra Hospital
Woolloongabba, Queensland, 4102, Australia
-
Rambam MC
Haifa, 3109601, Israel
-
Sarcoma Oncology Research Center
Santa Monica, California, 90403, United States
-
Severance Hospital, Yonsei University Health System
Seoul, 03722, South Korea
-
Stanford University Medical Center
Stanford, California, 94305, United States
-
Tel Aviv Sourasky Medical Center
Tel Aviv, 64239, Israel
-
The Christie NHS Foundation Trust
Manchester, M20 4BX, United Kingdom
-
The Netherlands Cancer Institute
Amsterdam, 1066CX, Netherlands
-
The Royal Marsden Hospital
London, SW3 6JJ, United Kingdom
-
UTSW Simmons Cancer Center
Dallas, Texas, 75235, United States
-
Universitair Ziekenhuis
Ghent, 9000, Belgium
-
Universitaire Ziekenhuizen Leuven
Leuven, Belgium
-
University of California at Los Angeles Hematology/Oncology
Santa Monica, California, 90404, United States
-
University of Michigan
Ann Arbor, Michigan, 48109, United States
-
University of Pittsburgh Medical Center, Hillman Cancer Center
Pittsburgh, Pennsylvania, 15232, United States
-
Vall d´Hebrón University Hospital
Barcelona, 08035, Spain
-
Washington University
St Louis, Missouri, 63110, United States
-
Western General Hospital
Edinburgh, Scotland, EH4 2XU, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a targeted procedure ease the burden of desmoid tumors?
- New hope for rare tumor patients: chemo delivered directly to desmoid growths
- New imaging method may spot tumor growth earlier after freezing treatment
- New drug ES014 targets desmoid tumors in Mid-Stage trial
- New pill shows promise in slowing rare Cancer's growth
- Last-Resort drug access for rare tumor patients